Valuation: Evofem Biosciences, Inc.

Market Cap 1.02M 896K 842K 770K 1.44M 97.75M 1.45M 10.11M 3.92M 49.84M 3.83M 3.75M 162M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.44M 48.66M 45.74M 41.82M 78.14M 5.31B 78.72M 549M 213M 2.71B 208M 204M 8.78B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day+7.59%
1 week+14.86%
Current month+3.03%
1 month+13.33%
3 months-0.64%
6 months+1.19%
Current year-10.53%
1 week 0.01
Extreme 0.007
0.01
1 month 0.01
Extreme 0.007
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
0.23
5 years 0
Extreme 0.0008
1,537.5
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 31/12/2017
Director of Finance/CFO 49 12/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 31/12/2017
Director/Board Member 58 31/12/2017
Date Insider Type Main position Quantity % Market Cap. Importance
12/01/24 Sell

Chief Financial Officer

104 0.0010%
21/12/23 Sell

Director

10 0.0001%
13/04/23 Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
+7.59%+14.86%-40.64%-94.33% 1.02M
-1.59%+1.31%+54.31%+108.71% 1,043B
-0.79%-0.06%+51.27%+66.67% 649B
-0.56%+0.62%+18.66%+70.80% 469B
-0.25%+0.19%+36.95%+45.54% 355B
+0.98%+2.91%+20.59%+27.14% 270B
-1.91%+2.42%+10.41%+11.04% 262B
-1.17%+7.60%+41.20%+51.75% 222B
-1.43%+1.93%+31.58%+101.16% 189B
-2.53%-7.47%-32.63%-60.41% 175B
Average -0.11%+1.98%+19.17%+32.81% 363.3B
Weighted average by Cap. -0.99%+2.19%+35.63%+65.02%

Financials

2024 2025
Net sales 19.36M 16.99M 15.98M 14.61M 27.29M 1.85B 27.5M 192M 74.39M 946M 72.71M 71.12M 3.07B 20.18M 17.71M 16.65M 15.22M 28.45M 1.93B 28.66M 200M 77.54M 986M 75.79M 74.13M 3.2B
Net income -8.86M -7.78M -7.31M -6.68M -12.49M -849M -12.58M -87.8M -34.04M -433M -33.27M -32.54M -1.4B 391K 343K 323K 295K 551K 37.45M 555K 3.87M 1.5M 19.1M 1.47M 1.44M 61.91M
Net Debt 45.84M 40.23M 37.82M 34.58M 64.61M 4.39B 65.09M 454M 176M 2.24B 172M 168M 7.26B 54.42M 47.76M 44.9M 41.05M 76.7M 5.21B 77.27M 539M 209M 2.66B 204M 200M 8.62B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
22/09/26 US$0.007700 +0.65% 7,025
21/09/26 US$0.007650 +3.38% 132
18/09/26 US$0.007400 -5.13% 100,678
17/09/26 US$0.007800 -1.27% 65,298
16/09/26 US$0.007900 +6.76% 116

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!